Allergan Raises Profit Forecast as Valeant Pursues Bid

Allergan Inc. raised its earnings forecast, bolstering the drugmaker’s defense against Valeant Pharmaceuticals International Inc.’s hostile takeover attempt.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.